Plain-language definitions of the documents, standards and abbreviations used in regulatory submissions, medical writing and pharmacovigilance, each with a link to the official source.
A
- Aggregate report
- An aggregate report is a periodic safety document that evaluates the cumulative safety data for a medicine over a defined interval, rather than describing a single case. The main types are the DSUR during clinical development and the PBRER, PSUR and PADER after approval.
C
- CCDS (Company Core Data Sheet)
- A Company Core Data Sheet (CCDS) is a document prepared by the marketing authorisation holder that contains the company's core information on a product's safety, indications, dosing and pharmacology. It is the company's reference for national labels, and its safety section, the Company Core Safety Information, is commonly used as the reference information for periodic safety reports.
- CSR (Clinical Study Report)
- A Clinical Study Report (CSR) is the full written account of one clinical study: its design, conduct, statistical analysis, and efficacy and safety results. Its structure and content are set out in ICH E3, and CSRs are placed in Module 5 of the CTD.
- CTD (Common Technical Document)
- The Common Technical Document (CTD) is the harmonised format for organising the quality, nonclinical and clinical information in a marketing application. It is defined in ICH M4 and has five modules, of which Modules 2 to 5 are common to all ICH regions.
D
- DSUR (Development Safety Update Report)
- A Development Safety Update Report (DSUR) is the annual safety report for a drug in clinical development. It presents the safety information from all clinical trials of the investigational product that were ongoing or completed during the reporting period, and is submitted to the health authorities overseeing those trials.
E
- eCTD (electronic Common Technical Document)
- The electronic Common Technical Document (eCTD) is the standard electronic format for submitting CTD-structured applications to health authorities. It adds an XML backbone and lifecycle management to the CTD, and is defined in ICH M8.
I
- IB (Investigator's Brochure)
- An Investigator's Brochure (IB) is a compilation of the clinical and nonclinical data on an investigational product that are relevant to its study in humans. It gives investigators the information they need to understand the rationale for a trial and to manage its risks.
- ICSR (Individual Case Safety Report)
- An Individual Case Safety Report (ICSR) is a report of one or more suspected adverse reactions to a medicine in a single patient at a specific point in time. ICSRs are exchanged electronically between companies and regulators in the ICH E2B(R3) format.
- IND (Investigational New Drug application)
- An Investigational New Drug application (IND) is the submission a sponsor makes to the US FDA before starting clinical trials of a new drug or biologic in the United States. Trials may begin 30 days after the FDA receives the IND, unless the agency places the study on clinical hold.
M
- Module 3 (CTD Quality)
- Module 3 is the Quality section of the Common Technical Document. It contains the chemistry, manufacturing and controls (CMC) information for the drug substance and the drug product, and is summarised in the Quality Overall Summary in Module 2.3.
N
- NDA (New Drug Application)
- A New Drug Application (NDA) is the application a sponsor submits to the US FDA for approval to market a new drug in the United States. It presents the evidence that the drug is safe and effective for its proposed use and that it can be manufactured to a consistent quality.
P
- PADER (Periodic Adverse Drug Experience Report)
- A Periodic Adverse Drug Experience Report (PADER) is the post-marketing periodic safety report that holders of approved US drug applications submit to the FDA. It is required quarterly for the first three years after approval and annually after that.
- PBRER (Periodic Benefit-Risk Evaluation Report)
- A Periodic Benefit-Risk Evaluation Report (PBRER) is the post-approval periodic report in which a marketing authorisation holder evaluates new safety information in the context of a product's cumulative benefit-risk profile. It is defined in ICH E2C(R2) and replaced the earlier PSUR format.
- PSUR (Periodic Safety Update Report)
- A Periodic Safety Update Report (PSUR) is the post-approval periodic safety report submitted to regulators. The EU still uses the name PSUR, and its format and content are based on the PBRER defined in ICH E2C(R2).
Q
- QOS (Quality Overall Summary)
- The Quality Overall Summary (QOS) is the Module 2.3 summary of the chemistry, manufacturing and controls information presented in Module 3 of the CTD. It follows the scope and outline of Module 3 and should not include information that is not already in Module 3 or elsewhere in the dossier.

